Alector Plummets After Alzheimer's Drug Trial Fails Primary Endpoint
Shares of Alector tumbled in after-hours trading after the company said its Alzheimer drug candidate, AL002, failed to meet its phase 2 primary endpoint of slowing clinical progression of the disease. The stock was down 33.6% to $2.63 in late trading, well under its 52-week low of $3.49.
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the ...
Alector reported a Phase 2 failure for an AbbVie-partnered Alzheimer’s program Monday afternoon and said it will ...
南旧金山 - 专注于神经退行性疾病的生物科技公司Alector, Inc.
Alector ( (ALEC) ) has released its Q3 earnings. Here is a breakdown of the information Alector presented to its investors.Don't Miss our Black ...
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology ...
Investing.com -- Alector Inc.宣布，其用于早期阿尔茨海默症治疗的AL002药物的二期临床试验未能达到减缓疾病进展的主要目标。受此消息影响，该公司股价在盘后交易中暴跌32%。 这家生物制药公司表示，由于试验未能达到主要终点，将终止AL002的长期延伸研究。针对这一发展，Alector还透露计划裁减约17%的员工。
Alector是一家专注于开发针对神经变性疾病治疗方案的生物制药公司。根据最近发布的财报，公司在第三季度实现营业收入1534万美元，但净利润为负，亏损达到4222万美元，每股亏损0.43美元。从市盈率来看，其为负3.08倍，显示出公司当前的财务状况远未达到盈利的水平。这种盈利能力的缺失无疑是今天股价下跌的一个重要原因。
Alector has launched an $208 million stock market offering as it ramps up clinical trials with AbbVie into a drug that aims to tackle Alzheimer’s by modifying the brain’s immune system.
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the Company ...
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback